[go: up one dir, main page]

BR9714002A - Pirróis como inibidores de spla2 - Google Patents

Pirróis como inibidores de spla2

Info

Publication number
BR9714002A
BR9714002A BR9714002-3A BR9714002A BR9714002A BR 9714002 A BR9714002 A BR 9714002A BR 9714002 A BR9714002 A BR 9714002A BR 9714002 A BR9714002 A BR 9714002A
Authority
BR
Brazil
Prior art keywords
pyrroles
spla2 inhibitors
spla
inhibitors
spla2
Prior art date
Application number
BR9714002-3A
Other languages
English (en)
Inventor
Nicholas James Bach
Robert Delane Dillard
Susan Elizabeth Draheim
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9714002A publication Critical patent/BR9714002A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Patente de Invenção:<B>"PIRRóIS COMO INIBIDORES DE sPLA~ 2~"<D>. é descrita uma classe de novos pirróis em conjunto com a utilização de tais compostos para a inibição da liberação de ácidos graxos medidas pela sPLA~ 2~, para tratamento de condições tais como o choque séptico.
BR9714002-3A 1996-12-10 1997-12-09 Pirróis como inibidores de spla2 BR9714002A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3329096P 1996-12-10 1996-12-10
PCT/US1997/022625 WO1998025609A1 (en) 1996-12-10 1997-12-09 PYRROLES AS sPLA2 INHIBITORS

Publications (1)

Publication Number Publication Date
BR9714002A true BR9714002A (pt) 2000-05-16

Family

ID=21869573

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9714002-3A BR9714002A (pt) 1996-12-10 1997-12-09 Pirróis como inibidores de spla2

Country Status (13)

Country Link
US (1) US5919774A (pt)
EP (1) EP0983064B1 (pt)
JP (1) JP2001505915A (pt)
KR (1) KR20000069377A (pt)
AT (1) ATE246501T1 (pt)
AU (1) AU5598398A (pt)
BR (1) BR9714002A (pt)
CA (1) CA2274571A1 (pt)
DE (1) DE69724009T2 (pt)
ES (1) ES2203828T3 (pt)
HU (1) HUP0000167A3 (pt)
IL (1) IL130338A0 (pt)
WO (1) WO1998025609A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407104B1 (en) 1998-03-31 2002-06-18 Shionogi & Co., Ltd. Pyrrolo[1,2-a]pyrazine spla2 inhibitor
CN1302300A (zh) 1998-05-21 2001-07-04 盐野义制药株式会社 吡咯并[1,2－b]哒嗪sPLA2抑制剂
US6325991B1 (en) 1998-08-24 2001-12-04 Susan E. Draheim Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2
US7098237B1 (en) 1998-10-14 2006-08-29 Shionogi & Co., Ltd. Remedies for ischemia reperfusion injury
AU6015600A (en) 1999-07-19 2001-02-05 Shionogi & Co., Ltd. Tricyclic compounds having spla2-inhibitory activities
AU6023200A (en) 1999-08-02 2001-02-19 Shionogi & Co., Ltd. Tricyclic compounds having spla2-inhibitory activities
JP4623483B2 (ja) 1999-08-23 2011-02-02 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有するピロロトリアジン誘導体
US7026318B2 (en) 2000-06-29 2006-04-11 Shionogi & Co., Ltd. Compounds exhibiting X-type sPLA2 inhibiting effect
AU2001267825A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
JP2004505982A (ja) * 2000-08-04 2004-02-26 イーライ・リリー・アンド・カンパニー 新規なｓＰＬＡ２インヒビター
TWI314457B (pt) 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
EP2322501B1 (en) 2002-01-08 2015-08-05 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
CN101307017A (zh) 2002-03-08 2008-11-19 帕拉特克药品公司 氨基-甲基取代的四环素类化合物
CA2479877C (en) 2002-03-21 2012-08-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP2345637A3 (en) 2002-07-12 2012-02-15 Paratek Pharmaceuticals, Inc. 3, 10, and 12a substituted tetracycline compounds
US20050137174A1 (en) 2003-07-09 2005-06-23 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
US20050143352A1 (en) 2003-07-09 2005-06-30 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US7786099B2 (en) * 2004-01-15 2010-08-31 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
EP2284153A3 (en) 2004-10-25 2012-03-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP2301912A3 (en) 2004-10-25 2012-07-11 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
WO2007014154A2 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
ES2463457T3 (es) 2006-12-21 2014-05-28 Paratek Pharmaceuticals, Inc. Derivados de la tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias
DK2120963T3 (en) 2006-12-21 2019-01-14 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS
EP2216323A3 (en) 2007-04-27 2010-12-29 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
BRPI0823405A2 (pt) * 2007-07-06 2012-12-25 Paratek Pharmaceuticals, Inc. mÉtodos para sintetizar compostos de tetraciclina substituÍda
TW202332671A (zh) 2008-05-19 2023-08-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
NZ603568A (en) 2008-08-08 2014-05-30 Tetraphase Pharmaceuticals Inc C7-fluoro substituted tetracycline compounds
CN107021887A (zh) 2009-05-08 2017-08-08 四相制药公司 四环素类化合物
JP5944825B2 (ja) 2009-08-28 2016-07-05 テトラフェース ファーマシューティカルズ，インコーポレイテッド テトラサイクリン化合物
PL2552890T3 (pl) 2010-03-31 2017-07-31 Tetraphase Pharmaceuticals, Inc. Policykliczne związki tetracyklinowe
SMT201900096T1 (it) 2012-08-31 2019-02-28 Tetraphase Pharmaceuticals Inc Composti di tetracicline
US10961190B2 (en) 2016-10-19 2021-03-30 Tetraphase Pharmaceuticals, Inc. Crystalline forms of eravacycline
US20210395198A1 (en) 2018-11-09 2021-12-23 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1083044A (en) * 1976-05-04 1980-08-05 Stewart Wong Antiarthritic potentiation
DE3629929A1 (de) * 1986-09-03 1988-03-10 Thomae Gmbh Dr K Neue sulfonamido-aethylverbindungen, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0300688A1 (en) * 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
US5260322A (en) * 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US5187168A (en) * 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
AU688458B2 (en) * 1994-04-01 1998-03-12 Eli Lilly And Company 1H-indole-3-glyoxylamide sPLA2 inhibitors

Also Published As

Publication number Publication date
EP0983064A1 (en) 2000-03-08
HUP0000167A2 (hu) 2000-09-28
HUP0000167A3 (en) 2001-01-29
EP0983064B1 (en) 2003-08-06
EP0983064A4 (en) 2001-01-31
AU5598398A (en) 1998-07-03
ATE246501T1 (de) 2003-08-15
ES2203828T3 (es) 2004-04-16
WO1998025609A1 (en) 1998-06-18
JP2001505915A (ja) 2001-05-08
IL130338A0 (en) 2000-06-01
DE69724009T2 (de) 2004-06-09
DE69724009D1 (de) 2003-09-11
US5919774A (en) 1999-07-06
CA2274571A1 (en) 1998-06-18
KR20000069377A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
BR9714002A (pt) Pirróis como inibidores de spla2
BR9713261A (pt) Tricìclicos substituìdos
ATE220394T1 (de) 1h-indol-3-glyoxylamid spla2 inhibitoren
BR9902365A (pt) Tricìclicos substituìdos
BR9508298A (pt) Inibidores de indolizina de spla2
BR9713993A (pt) Pirazóis como inibidores de fosfolipase a2 secretora não pancreática humana
ATE347362T1 (de) Bicyclische spla 2-inhibitoren
BR9713562A (pt) Fenil glioxamidas como inibidores de spla2
BR9901275A (pt) Triciclicos substituidos.
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
BR9713987A (pt) Fenil acetamidas como inibidores de spla2
EP1100492A4 (en) SPLA 2 INHIBITORS? INDOLE TYPE
ATE247119T1 (de) Substituierte pyrroloindole
DE60032774D1 (de) Spla2 inhibitoren
AU7053700A (en) Novel spla2 inhibitors
BR9612000A (pt) Naftil glioxamidas como inibidores de spla; &#39;

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1836 DE 14/03/2006.